{"id":"https://openalex.org/W4389953172","doi":"https://doi.org/10.1161/circ.148.suppl_1.12945","title":"Abstract 12945: Six-Month Adherence Among Early Inclisiran Initiators vs. Anti-PCSK9 mAbs Users: A Retrospective Analysis of US Claims Databases","display_name":"Abstract 12945: Six-Month Adherence Among Early Inclisiran Initiators vs. Anti-PCSK9 mAbs Users: A Retrospective Analysis of US Claims Databases","publication_year":2023,"publication_date":"2023-11-07","ids":{"openalex":"https://openalex.org/W4389953172","doi":"https://doi.org/10.1161/circ.148.suppl_1.12945"},"language":"en","primary_location":{"id":"doi:10.1161/circ.148.suppl_1.12945","doi":"https://doi.org/10.1161/circ.148.suppl_1.12945","is_oa":false,"landing_page_url":"https://doi.org/10.1161/circ.148.suppl_1.12945","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102594487","display_name":"Charlene Niu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Charlene Niu","raw_affiliation_strings":["Novartis Pharmaceuticals, Wellesley, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, Wellesley, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5092691146","display_name":"Akhil Parlapalli","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Akhil Parlapalli","raw_affiliation_strings":["Komodo Health, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Komodo Health, San Francisco, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073589613","display_name":"Joseph Neenan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joseph Neenan","raw_affiliation_strings":["Komodo Health, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Komodo Health, San Francisco, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035001170","display_name":"Xinshuo Ma","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xinshuo Ma","raw_affiliation_strings":["Komodo Health, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Komodo Health, San Francisco, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002350845","display_name":"Abena A. Osei-Wusu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Abena Osei-Wusu","raw_affiliation_strings":["Novartis Pharmaceuticals Corp, East Hanover"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corp, East Hanover","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100752301","display_name":"Jina Park","orcid":"https://orcid.org/0000-0002-7410-1985","observed_orcids":["https://orcid.org/0000-0002-7410-1985","https://orcid.org/0000-0002-7682-7253"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jina Park","raw_affiliation_strings":["Komodo Health, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Komodo Health, San Francisco, CA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039213962","display_name":"Sean C. McElligott","orcid":"https://orcid.org/0000-0001-9453-1432","observed_orcids":["https://orcid.org/0000-0001-9453-1432"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sean McElligott","raw_affiliation_strings":["Novartis, Doylestown, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis, Doylestown, PA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"148","issue":"Suppl_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.6133000254631042,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.6133000254631042,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.37619999051094055,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/inclisiran","display_name":"inclisiran","score":0.9729999899864197},{"id":"https://openalex.org/keywords/alirocumab","display_name":"alirocumab","score":0.9409999847412109},{"id":"https://openalex.org/keywords/evolocumab","display_name":"evolocumab","score":1.0},{"id":"https://openalex.org/keywords/pcsk9-inhibitors","display_name":"PCSK9 inhibitors","score":0.9340000152587891},{"id":"https://openalex.org/keywords/anti-pcsk9-monoclonal-antibodies","display_name":"anti-PCSK9 monoclonal antibodies","score":0.9179999828338623},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.8410000205039978},{"id":"https://openalex.org/keywords/proportion-of-days-covered","display_name":"proportion of days covered","score":0.8230000138282776},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.75},{"id":"https://openalex.org/keywords/atherosclerotic-cardiovascular-disease","display_name":"atherosclerotic cardiovascular disease","score":0.9449999928474426},{"id":"https://openalex.org/keywords/statin-adherence","display_name":"statin adherence","score":0.49799999594688416},{"id":"https://openalex.org/keywords/hypercholesterolemia","display_name":"hypercholesterolemia","score":0.7429999709129333},{"id":"https://openalex.org/keywords/lipid-lowering-therapy","display_name":"lipid-lowering therapy","score":0.6790000200271606},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.5389999747276306},{"id":"https://openalex.org/keywords/claims-data","display_name":"claims data","score":0.492000013589859}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9561684131622314},{"id":"https://openalex.org/C2780902209","wikidata":"https://www.wikidata.org/wiki/Q4726914","display_name":"Alirocumab","level":5,"score":0.7677323818206787},{"id":"https://openalex.org/C2778114629","wikidata":"https://www.wikidata.org/wiki/Q15623825","display_name":"Evolocumab","level":5,"score":0.632779598236084},{"id":"https://openalex.org/C2776839432","wikidata":"https://www.wikidata.org/wiki/Q954845","display_name":"Statin","level":2,"score":0.6221860647201538},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.5903992056846619},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.5437144637107849},{"id":"https://openalex.org/C2780948078","wikidata":"https://www.wikidata.org/wiki/Q21130010","display_name":"PCSK9","level":5,"score":0.5275534987449646},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48671868443489075},{"id":"https://openalex.org/C77088390","wikidata":"https://www.wikidata.org/wiki/Q8513","display_name":"Database","level":1,"score":0.47824373841285706},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.43899303674697876},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.2408793866634369},{"id":"https://openalex.org/C62746215","wikidata":"https://www.wikidata.org/wiki/Q14890615","display_name":"Apolipoprotein B","level":3,"score":0.18762046098709106},{"id":"https://openalex.org/C2780072125","wikidata":"https://www.wikidata.org/wiki/Q28350","display_name":"Lipoprotein","level":3,"score":0.10482394695281982},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C2780745583","wikidata":"https://www.wikidata.org/wiki/Q1316030","display_name":"Apolipoprotein A1","level":4,"score":0.0},{"id":"https://openalex.org/C43554185","wikidata":"https://www.wikidata.org/wiki/Q425649","display_name":"LDL receptor","level":4,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1161/circ.148.suppl_1.12945","doi":"https://doi.org/10.1161/circ.148.suppl_1.12945","is_oa":false,"landing_page_url":"https://doi.org/10.1161/circ.148.suppl_1.12945","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4400959357","https://openalex.org/W4389958704","https://openalex.org/W7164184848","https://openalex.org/W7128051866","https://openalex.org/W4413268659","https://openalex.org/W4416601006","https://openalex.org/W7169772098","https://openalex.org/W7168928262","https://openalex.org/W2622520030","https://openalex.org/W7127640811"],"abstract_inverted_index":{"Introduction:":[0],"Poor":[1,207],"adherence":[2,68,78,208,250,275,324],"with":[3,14,38,273,303,335],"statins":[4],"is":[5,20,50,120,329],"an":[6,28,55],"obstacle":[7],"in":[8,131,172,231,237,243,293],"achieving":[9],"LDL-C":[10,47,343],"targets":[11],"for":[12,36,82,167,253,262,267,280,285,289,333],"patients":[13,83,130,219,235,272,292,319,334],"atherosclerotic":[15],"cardiovascular":[16],"disease":[17],"(ASCVD).":[18],"Inclisiran":[19,328],"a":[21,121,164,300,304,330],"first-in-class,":[22],"long-acting,":[23],"small-interfering":[24],"RNA":[25],"approved":[26],"as":[27,182,211],"adjunct":[29],"to":[30],"diet":[31],"and":[32,61,136,163,229,241,264,287],"maximally":[33],"tolerated":[34],"statin":[35],"adults":[37],"ASCVD":[39,336],"or":[40,92,94,99,170],"heterozygous":[41],"familial":[42],"hypercholesterolemia":[43],"who":[44,84,337],"require":[45],"additional":[46],"lowering.":[48],"It":[49],"initially":[51],"administered":[52],"subcutaneously":[53],"by":[54,194,198,259,283],"HCP,":[56],"again":[57],"at":[58,79,255],"3":[59],"months":[60,81,147,157,203,222],"then":[62],"twice":[63],"yearly.":[64],"Real-world":[65],"studies":[66],"assessing":[67],"of":[69,148,185,191,217,223,271,307],"inclisiran":[70,233,254,295,321],"are":[71],"limited.":[72],"Hypothesis:":[73],"This":[74,104],"study":[75,107],"evaluated":[76],"treatment":[77],"6":[80,156],"newly":[85],"initiated":[86],"inclisiran,":[87,168,281],"alirocumab":[88,239,263,286],"(every":[89,96],"2":[90,97],"weeks":[91,98],"1/month)":[93,100],"evolocumab":[95,171,245],"since":[101],"2022.":[102],"Methods:":[103],"retrospective,":[105],"observational":[106,200],"utilized":[108],"the":[109,132,153,160,173,183,189,195,199,226,232,238,244,294],"US":[110,133],"Komodo":[111,118],"Health":[112,119],"database":[113,125],"from":[114,134],"1/1/21":[115],"-":[116,177],"2/8/23.":[117],"nationally":[122],"representative":[123],"longitudinal":[124],"that":[126],"captures":[127],"330":[128],"million":[129],"open":[135],"closed":[137],"administrative":[138],"databases.":[139],"Patients":[140],"were":[141,230,236],"aged":[142],"\u226518":[143],"years,":[144],"had":[145,220,322],"12":[146],"continuous":[149],"enrollment":[150],"(CE)":[151],"before":[152],"index":[154,161,205,227],"date,":[155],"CE":[158,224],"after":[159,204,225],"date":[162,228],"first":[165],"claim":[166],"alirocumab,":[169],"identification":[174],"period":[175,201],"(1/1/22":[176],"10/31/22).":[178],"Adherence":[179],"was":[180,209,251,278],"defined":[181,210],"proportion":[184,270],"days":[186,192,310],"covered":[187,193],"(PDC):":[188],"number":[190],"drug":[196],"divided":[197],"(6":[202],"date).":[206],"PDC":[212],"<80%.":[213],"Results:":[214],"A":[215],"total":[216],"981":[218],"\u22656":[221],"cohort;11,330":[234],"cohort":[240,296],"30,515":[242],"cohort.":[246],"Mean":[247],"(SD)":[248],"6-month":[249],"highest":[252],"0.85":[256],"(0.22)":[257],"followed":[258,282],"0.72":[260],"(0.30)":[261,266],"0.70":[265],"evolocumab.":[268,290],"The":[269],"high":[274],"(PDC":[276],"\u22650.8)":[277],"69.9%":[279],"51.0%":[284],"48.6%":[288],"Of":[291],"(n=981),":[297],"70.9%":[298],"received":[299],"second":[301],"dose":[302],"mean":[305],"time":[306],"90.9":[308],"(32.0)":[309],"between":[311],"doses.":[312],"Conclusions:":[313],"Early":[314],"evidence":[315],"post":[316],"launch":[317],"shows":[318],"initiating":[320],"higher":[323],"vs":[325],"anti-PCSK9":[326],"mAbs.":[327],"new":[331],"option":[332],"may":[338],"have":[339],"difficulty":[340],"reaching":[341],"their":[342],"target.":[344]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2}],"updated_date":"2026-09-24T07:57:37.273135","created_date":"2023-12-20T00:00:00"}